TO THE EDITOR
We read with interest the letter by Andersen et al 1 reporting three cases of chronic myeloid leukemia (CML) with clonal Philadelphia negative (PhÀ) hematopoiesis arising after treatment with imatinib mesylate and would like to describe a further interesting patient with some similar features, but a fatal outcome.
The patient was a 42-year-old man who first presented in March 1995 with Philadelphia positive (Ph+) chronic phase CML.
Karyotyping at presentation showed 46,XY,t(9;22)(q34;q11) as the sole abnormality in eight metaphases analysed. He was initially treated with hydroxyurea and interferon, and 4 months later underwent an HLA-identical sibling bone marrow transplant from his brother, conditioned with TBI and cyclophosphamide. He suffered cytogenetic relapse 10 months after transplantation and failed to respond to two donor lymphocyte infusions (DLIs). His counts were controlled over the next 42 months with interferon and cytarabine. However, throughout this period he remained 100% Ph+, with up to four new Ph+ related clones detected, suggesting acceleration: (46XY,t(9;22)(q34;q11)[1]/46XY,t(9;22) (q34;q11),(t11;14)(q23;q11) [3] /46XY,t(4;der(9)t(9;22)(q34;q11);14) (q31?.3;q32;q11),der(22)t(9;22)(q34;q11)[9]/46XY,t(1;19)(q3?2;q13), t(9;22)(q34;q11) [3] /46XY[1]). In December 2000, he was entered into the Novartis expanded access accelerated phase imatinib mesylate (Glivec) trial (protocol 0114). Following 9 months of therapy with imatinib mesylate his marrow was shown to have become 100% PhÀ (10 metaphases including three cells with unrelated nonclonal abnormalities). After 15 months of treatment with imatinib mesylate, he developed pancytopenia with marked trilineage dysplasia, 15% blasts and multiple, related, cytogenetic clonal abnormalities including monosomies 5, 7 and 16 (42-45,XY,À5,À7,?psudic (12;8) (p13;q10),À16,psudic(17;8)(p13;?q10),+mar[cp5]/42-43,XY,À5, À7,add(12)(p12-13), À16, psudic (17;8)(p13;?q10), +3mar[cp3] / 46XY[1],). Interestingly, these clones remained 100% PhÀ with low ratios of bcr-abl/abl(0.1-0.895) consistent with a PhÀ karyotype . None of these clones was related to the previously identified Ph+ clones. He progressed rapidly to secondary acute myeloid leukemia (AML) and died having declined further therapy.
Our patient shared some features similar to those reported and reviewed by Andersen et al.
1 Most importantly, he developed new PhÀ cytogenetically unrelated clones during treatment with imatinib mesylate. However, we believe that this is the first time clinical myelodysplasia (MDS) has been described in association with this phenomenon. This case is complicated by the history of allogeneic transplantation. Features supporting the development of straightforward treatment-related myelodysplasia (t-MDS) include exposure to alkylating agent, the time period to development of MDS and complex cytogenetic abnormalities involving monosomy for 5 and 7. However, this diagnosis is rare after allogeneic transplantion. 2 We, therefore, suggest two alternative scenarios. Firstly, as proposed by Andersen et al, 1 the new PhÀ clones may represent a preleukemic stage of CML and treatment with imatinib mesylate, which specifically targets the Ph+ clone, conferred a growth advantage on these otherwise silent clones. Secondly, previous chemotherapy and radiotherapy may have caused or added further damage to normal or abnormal PhÀ stem cells. The clinical emergence of these clones was then selected for by treatment with imatinib mesylate. If so, this would have implications for the use of imatinib mesylate in combination treatment or as maintenance treatment post-transplantation. This might be especially relevant after autografting when t-MDS is more frequently recognised. The PhÀ clone in our case was typical of t-MDS and, unlike the cases described by Andersen et al, did not include trisomy 8. Unfortunately, the allogeneic transplant was not sex mismatched and we were unable to ascertain if the MDS clone was of host or donor origin.
We accept that this case may simply represent a rare example of t-MDS post allografting. However, the onset in relation to the introduction of imatinib mesylate therapy, the emergence of the PhÀ unrelated clones on the background of a complete cytogenetic response of CML and the aggressive, rapidly fatal phenotype of the resultant MDS is of concern in the light of the observations of Andersen et al 1 and others, 3, 4 including an abstract by Marktel et al (The Haematology Journal 2002, 3, Suppl 1, 175).
To date these reports have described the development of new PhÀ clones, including monosomy 7, 4 but not the development of clinical MDS. We welcome further reports and suggest careful monitoring of patients when imatinib mesylate is used after previous leukemogenic therapy. 
